Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Pfizer, Inc. : Close to new upside potential

10/20/2020 | 11:57am EDT
long trade
Stop-loss triggered
Entry price : 37.39$ | Target : 44.7$ | Stop-loss : 33.9$ | Potential : 19.55%
Below the resistance zone that is currently being tested, the potential for new gains appears limited for shares in Pfizer Inc.. The stock's technical chart pattern suggests however that the level will be broken.
Investors have an opportunity to buy the stock and target the $ 44.7.
Pfizer, Inc. : Pfizer, Inc. : Close to new upside potential
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
  • In a short-term perspective, the company has interesting fundamentals.

  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Considering the small differences between the analysts' various estimates, the group's business visibility is good.
  • Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.

  • The share is close to its long-term resistance in weekly data. Therefore, the potential should be limited. However, a further bullish movement when crossing this resistance will be a positive signal.
  • The company is in debt and has limited leeway for investment
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
  • The company's enterprise value to sales, at 5.06 times its current sales, is high.

ę MarketScreener.com 2020

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials (USD)
Sales 2021 79 586 M - -
Net income 2021 18 722 M - -
Net Debt 2021 26 885 M - -
P/E ratio 2021 13,1x
Yield 2021 3,49%
Capitalization 253 B 253 B -
EV / Sales 2021 3,52x
EV / Sales 2022 4,25x
Nbr of Employees 78 500
Free-Float 59,2%
Upcoming event on PFIZER, INC.
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 24
Last Close Price 45,19 $
Average target price 43,82 $
Spread / Average Target -3,03%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
Frank A. D'Amelio Chief Financial Officer & EVP-Global Supply
Mikael Dolsten Chief Scientific Officer & Research President
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Aida Habtezion Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
PFIZER, INC.22.77%252 960
JOHNSON & JOHNSON10.15%456 367
ROCHE HOLDING AG14.56%340 460
NOVARTIS AG-0.36%223 613
NOVO NORDISK A/S43.21%222 926